8-K: Avalon GloboCare Secures $300,000 Through Preferred Stock Sale to Mast Hill Fund

Avalon GloboCare Corp. has entered into a securities purchase agreement with Mast Hill Fund, L.P. to sell 300 shares of Series C Convertible Preferred Stock for $300,000, yielding net proceeds of $290,000.

Summary

• Avalon GloboCare Corp. (the Company) entered into a Securities Purchase Agreement with Mast Hill Fund, L.P. (the Investor) on July 21, 2025.
• The Company agreed to issue and sell 300 shares of Series C Convertible Preferred Stock to the Investor for an aggregate purchase price of $300,000, at $1,000 per share.
• The Company will receive net proceeds of $290,000 at closing, after deducting $10,000 in offering expenses for the Investor's legal fees.
• The issuance of the Company's common stock upon conversion of the Series C Convertible Preferred Stock is contingent upon obtaining shareholder approval.
• The securities were offered and sold in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933.
• The Company intends to use the proceeds for working capital and general corporate purposes.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for the company's operations, which is a positive for liquidity. However, the use of convertible preferred stock and the associated potential for future dilution, coupled with the deduction for investor legal fees, temper the overall positive sentiment. The need for shareholder approval for conversion also introduces a degree of uncertainty.

Positives

• Secured $300,000 in gross proceeds, providing capital for working capital and general corporate purposes.
• The transaction provides $290,000 in net proceeds, enhancing liquidity.
• The capital infusion comes from an accredited investor, Mast Hill Fund, L.P., indicating investor confidence.

Negatives

• Net proceeds are reduced by $10,000 due to the Investor's legal fees, representing a 3.33% reduction from the gross purchase price.
• The conversion of preferred stock into common stock is subject to shareholder approval, introducing a potential delay or uncertainty for the Investor.
• The issuance of convertible preferred stock, which can convert into common stock, carries the potential for future dilution of existing common shareholders.

Risks

• The securities have not been registered under the 1933 Act or any state securities laws and are subject to transfer restrictions, limiting liquidity for the Buyer.
• The Buyer acknowledges substantial risks incident to the purchase and ownership of the Securities, including the possibility of total loss of investment.
• The Company's ability to issue common stock upon conversion of the preferred stock is contingent on obtaining shareholder approval, which may not be secured.
• Failure to maintain Nasdaq listing could negatively impact the Company's stock trading status.

Future Outlook

The Company plans to seek shareholder approval for the conversion of the Series C Convertible Preferred Stock into common stock at its next annual or special meeting. If initial approval is not obtained, the Company commits to holding additional shareholder meetings for up to 180 days to secure the necessary approval. The Company also intends to use commercially reasonable efforts to maintain its Nasdaq listing and conduct business in the ordinary course.

Industry Context

This capital raise through convertible preferred stock is a common financing strategy for biotechnology and healthcare companies like Avalon GloboCare, which often require significant capital for research, development, and operational expenses. Such transactions allow companies to secure funding while potentially deferring common stock dilution until specific conditions, like shareholder approval, are met. The involvement of an accredited investor like Mast Hill Fund, L.P. is typical for private placements in this sector.

Comparison to Industry Standards

• The use of convertible preferred stock for financing is a standard practice in the biotech and life sciences sectors, often employed by companies that may not yet have consistent revenue streams or are in growth phases, similar to how companies like Moderna or BioNTech raised early-stage capital before significant market penetration.
• The condition of shareholder approval for conversion is a common protective measure for existing common shareholders, ensuring transparency and governance, a practice seen across various industries, including technology and pharmaceuticals, when significant equity dilution is a possibility.
• The discount for investor legal fees ($10,000 on a $300,000 raise, or 3.33%) is within a typical range for private placement transaction costs, comparable to fees observed in similar small-to-mid cap biotech financing rounds.
• The reliance on Section 4(a)(2) and Rule 506(b) for unregistered sales is standard for private placements to accredited investors, aligning with how many early-stage or growth companies, such as those in the diagnostic or therapeutic development space, secure funding without a full public offering.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution of common stock upon conversion of the Series C Preferred Stock, contingent on shareholder approval. The capital raise provides funding that could support company operations and potentially enhance long-term value.
• Creditors: Improved liquidity from the capital raise may enhance the company's ability to meet its financial obligations.

Next Steps

• The Company will solicit shareholder approval for the conversion of Series C Convertible Preferred Stock into common stock at its next annual or special meeting.
• If shareholder approval is not obtained, the Company will hold additional shareholder meetings for up to 180 days to secure the approval.
• The Company will use the net proceeds of $290,000 for working capital and general corporate purposes.
• The Company will use commercially reasonable efforts to ensure its common stock remains continually listed on Nasdaq.

Key Dates

Recommendation

While the capital raise provides essential liquidity for Avalon GloboCare's operations, the terms involving convertible preferred stock and the contingent nature of common stock conversion (requiring shareholder approval) introduce uncertainty and potential future dilution. The deduction of investor legal fees from the gross proceeds also slightly diminishes the immediate benefit. Given these factors, a 'hold' recommendation is appropriate as investors should monitor the shareholder approval process and the company's use of funds before making further investment decisions. The transaction is a necessary step for the company but does not present a clear catalyst for significant immediate upside.

Keywords

Avalon GloboCare, ALBT, Securities Purchase Agreement, Convertible Preferred Stock, Series C Preferred Stock, Capital Raise, Mast Hill Fund, SEC Filing, 8-K, Biotechnology, Healthcare, Financing, Equity